9, Moskovskiy prosp.,At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

The QuaysAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Navigation HouseAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Northwick Park HospitalAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Lady Bay HouseAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Private Bag X09At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

63 Worraker StreetAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

One Kilmainham Square Dublin, 8 IrelandAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

The Quays 101-105 Oxford Rd Uxbridge, Middlesex, UB8 1LZ United KingdomAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

70 Sir John Rogerson's Quay Dublin, Dublin, D02 R296 IrelandAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

195 West Street Waltham, MA, 02451 United StatesAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

200 West Street Waltham, MA 02451 USAAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

1560 E. Chevy Chase DriveAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Suite B, Level 6At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Room 1406 & 1407, 14F, Tower AAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

METROPOLIS CENTERAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

8th Floor, Centre City TowerAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Wicker HouseAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

101 Windsor ParkAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

The Quays, 101-105 OXFORD RD UXBRIDGE, MIDDLESEX, UB8 1LZ United KingdomAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Blvd Manuel Avila Camacho No 191, 3rd floorAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Av. Del Libertador 2442, 2nd floor, OlivosAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Av. Brig. Faria LimaAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Avenida Americo VespucioAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

8/F, DLF CybercityAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

8th Floor, Building No: 14, MindspaceAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

MFAR Silver Line Tech ParkAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

5th & 6th FloorAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

51 Bras Basah RoadAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Parc des CollinesAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Ivanecka 15At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

190 rue CHAMPIONNETAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

200 Rue Leonard de VinciAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Kartäuserstrasse 47At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Hermina út 17At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Via Filippo Turati, 28At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Kestucio g. 65At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Herman Heijermansweg 20At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Marconich str. 6At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Osenny Bulvar 23At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

10 Shaumyana strAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Klare Cetkin 23/7At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Genova, 17-3 PlantaAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

9920 Pacific Heights Blvd.At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

University Research ParkAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

540 Lake Cook RoadAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Harbor Hospital Center, 7th FloorAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

4600 East West Highway, Suite 350At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

2 Federal StreetAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

900 Chelmsford StreetAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

433 Hackensack Ave, 10th FloorAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

50 Millstone RoadAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

2520 Meridian ParkwayAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

435 Devon Park DriveAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

5870 Trinity ParkwayAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

PO Box 92029At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

Unit 1104,, Level 11, Uptown 2At Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.

30/F, Unit G & HAt Parexel, speeding life-changing medicines to market begins by engaging patients With Heart™ With more than 20,000 life science professionals in 49 countries across six continents, Parexel’s people are the engine that drives clinical trial delivery, outcomes, and new medicines forward. We have made significant investment in our operations infrastructure to ensure consistent, predictable delivery all around the world as clinical research complexity continues to rise. Our trial execution framework integrates the latest innovations to efficiently manage increased research complexity, reach more patients while driving faster results for our customers and better outcomes for patients. And around the world, we’re investing today to develop a talent pool ready to deliver your next big breakthrough. The integration of clinical operations excellence and unparalleled regulatory consulting strength gives us an advantage when tackling the most complex trials in oncology, cell and gene therapies, rare diseases, and central nervous system disorders. We have a proven track record of strong performance in these areas, along with immunology, inflammation, and many more. We apply clinical operations and regulatory expertise to design clinical trials that help life-saving medicines reach patients sooner. From Phase I to Phase IV, global life sciences professionals work in partnership with biopharmaceutical sponsors to create trial experiences that are easier for patients to participate in and can serve as a viable care option for patients across a range of disease areas. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas while our innovation ecosystem offers solutions throughout the product lifecycle – optimising data quality, creating better clinical trial experiences, and improving operational efficiencies – with the goal of driving better results for our customers and outcomes for patients. With the people, insight, and operational excellence to support a thriving R&D community, Parexel works With HeartTM to treat patients with dignity and learn from their experiences, so every trial makes a difference. In 2021, Parexel was acquired by EQT and Goldman Sachs Asset Management. We are headquartered in Raleigh, North Carolina, and employ 20,815 professionals in 49 countries. We are united by a core value that we believe influences every aspect of our work: We Care. We care about our people, our customers, our sites, and our partners.